Historical Valuation
Olema Pharmaceuticals Inc (OLMA) is now in the Fair zone, suggesting that its current forward PS ratio of 1193.09 is considered Fairly compared with the five-year average of -6.26. The fair price of Olema Pharmaceuticals Inc (OLMA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：27.28
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Olema Pharmaceuticals Inc (OLMA) has a current Price-to-Book (P/B) ratio of 5.64. Compared to its 3-year average P/B ratio of 2.21 , the current P/B ratio is approximately 155.88% higher. Relative to its 5-year average P/B ratio of 2.16, the current P/B ratio is about 161.56% higher. Olema Pharmaceuticals Inc (OLMA) has a Forward Free Cash Flow (FCF) yield of approximately -6.77%. Compared to its 3-year average FCF yield of -23.62%, the current FCF yield is approximately -71.33% lower. Relative to its 5-year average FCF yield of -24.78% , the current FCF yield is about -72.67% lower.
P/B
Median3y
2.21
Median5y
2.16
FCF Yield
Median3y
-23.62
Median5y
-24.78
Competitors Valuation Multiple
AI Analysis for OLMA
The average P/S ratio for OLMA competitors is 452.46, providing a benchmark for relative valuation. Olema Pharmaceuticals Inc Corp (OLMA.O) exhibits a P/S ratio of 1193.09, which is 163.69% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for OLMA
1Y
3Y
5Y
Market capitalization of OLMA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OLMA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is OLMA currently overvalued or undervalued?
Olema Pharmaceuticals Inc (OLMA) is now in the Fair zone, suggesting that its current forward PS ratio of 1193.09 is considered Fairly compared with the five-year average of -6.26. The fair price of Olema Pharmaceuticals Inc (OLMA) is between to according to relative valuation methord.
What is Olema Pharmaceuticals Inc (OLMA) fair value?
OLMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Olema Pharmaceuticals Inc (OLMA) is between to according to relative valuation methord.
How does OLMA's valuation metrics compare to the industry average?
The average P/S ratio for OLMA's competitors is 452.46, providing a benchmark for relative valuation. Olema Pharmaceuticals Inc Corp (OLMA) exhibits a P/S ratio of 1193.09, which is 163.69% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Olema Pharmaceuticals Inc (OLMA) as of Jan 09 2026?
As of Jan 09 2026, Olema Pharmaceuticals Inc (OLMA) has a P/B ratio of 5.64. This indicates that the market values OLMA at 5.64 times its book value.
What is the current FCF Yield for Olema Pharmaceuticals Inc (OLMA) as of Jan 09 2026?
As of Jan 09 2026, Olema Pharmaceuticals Inc (OLMA) has a FCF Yield of -6.77%. This means that for every dollar of Olema Pharmaceuticals Inc’s market capitalization, the company generates -6.77 cents in free cash flow.
What is the current Forward P/E ratio for Olema Pharmaceuticals Inc (OLMA) as of Jan 09 2026?
As of Jan 09 2026, Olema Pharmaceuticals Inc (OLMA) has a Forward P/E ratio of -11.64. This means the market is willing to pay $-11.64 for every dollar of Olema Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Olema Pharmaceuticals Inc (OLMA) as of Jan 09 2026?
As of Jan 09 2026, Olema Pharmaceuticals Inc (OLMA) has a Forward P/S ratio of 1193.09. This means the market is valuing OLMA at $1193.09 for every dollar of expected revenue over the next 12 months.